跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Santen Oy

首页临床试验发起方与机构Santen Oy

Santen Oy

ACTIVE

Østbanegade 123, København Ø, Hovedstaden, 芬兰www.santen.fiSubsidiary

隶属于 SANTEN PHARMACEUTICAL CO., LTD.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

41

32 进行中

药物批准

35

批准总数

监管机构

4

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

13

31.7%

3 期

6

14.6%

试验状态分布

进行中（未招募）

32

78.0%

已完成

9

21.9%

相关临床试验

该机构主办的试验（41）

A clinical trial on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from Ganfort¿eye drops to Taptiqom¿ eye drops.

进行中（未招募）

Jan 2021123 名受试者

Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

进行中（未招募）

May 201618 名受试者

Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

进行中（未招募）

Jan 201618 名受试者

Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

进行中（未招募）

Dec 201518 名受试者

A clinical trial on the changes in ocular signs and symptoms in patientswith ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops to Taptiqom® eye drops.

进行中（未招募）

Apr 2015120 名受试者

A clinical trial on the changes in ocular signs and symptoms in patientswith ocular hypertension or open-angle glaucoma switched from Ganfort® eye drops to Taptiqom® eye drops.

进行中（未招募）

Feb 2015120 名受试者

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Jun 201417 名受试者

Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.

进行中（未招募）

May 201418 名受试者

第 1 页，共 6 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

2

药物批准

EMA

European Medicines Agency

12

药物批准

SFDA

Saudi Food and Drug Authority

3

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

18

药物批准

近期批准

ROCLANDA 50 MICROGRAMOS/ML + 200 MICROGRAMOS/ML COLIRIO EN SOLUCION

Tafluprost and Timolol Maleate Eye Drops

CATIOLANZE 50 MICROGRAMOS/ML COLIRIO EN EMULSION

ROCLANDA 50 MICROGRAMOS/ML + 200 MICROGRAMOS/ML COLIRIO EN SOLUCION

Ciclosporin Eye Drops （III）

资讯

暂无资讯文章

本页目录

概览
相关临床试验41
药物批准35
资讯

返回机构列表